Ovarian cancer often goes undetected for a long time. In seven out of 10 patients, the tumor has already formed secondary ...

Ovarian cancer is one of the most common forms of cancer, a type that usually remains undiagnosed for a while in many ...

The FDA-approved drug combination specifically targets low-grade serous ovarian cancer, which primarily affects younger women ...

In this systematic review and meta-analysis, researchers examined outcomes among advanced ovarian cancer patients who received interval debulking surgery compared to primary debulking surgery.

A panelist discusses how tumor heterogeneity (both spatial and temporal) affects molecular testing reliability in ovarian cancer, highlighting that although most biomarkers show little heterogeneity, ...

University of Manchester researchers have shown that analysis of fluid flushed through a fallopian tube holds promise for ...

July 31, 2025, NEW YORK – The immune system is a major determinant of how patients respond to standard treatments for ovarian cancer, the leading cause of death from gynecological malignancies. But ...

High HSP60 expression in ovarian cancer is linked to poor prognosis and aggressive tumor features, including advanced FIGO stage and lymph node metastasis. Patients with elevated HSP60 levels exhibit ...

In the future, scientists could use drugs made from cannabis to fight ovarian cancer. A team of scientists testing the ...

ORR for BI-1808 combined with pembrolizumab represents a meaningful improvement over pembrolizumab monotherapy in recurrent ...